Chennai-based generic pharma major Orchid Chemicals & Pharmaceuticals Ltd has received approvals to market its Piperacillin and Tazobactam (anti-biotic drugs) injections in European Union nations.
Orchid had filed an marketing authorisation (seeking approvals for marketing) with the UK Medicines and Healthcare products Regulatory Agency (MHRA) earlier, the company informed the BSE today.
“This is an important milestone in our regulated generics plan. Through this approval we are expanding into a new range of premium pencillin injectables and also foraying into the EU generics market. We are launching this product through our exclusive marketing alliance with Hospira for the EU market and given the limited competition envisaged in this product we are confident of a robust market share and revenue stream,” Orchid Managing Director K Raghavendra Rao said.
